Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1991 1
1996 2
1997 1
1998 1
1999 2
2000 2
2001 2
2002 6
2003 4
2004 4
2005 8
2006 6
2007 2
2008 5
2009 3
2010 12
2011 6
2012 5
2013 8
2014 6
2015 9
2016 8
2017 12
2018 11
2019 9
2020 9
2021 12
2022 9
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: . Clear all
Proximity search should include two or more words. Proximity operator ignored :~0
Page 1
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barre syndrome.
van Doorn PA, Van den Bergh PYK, Hadden RDM, Avau B, Vankrunkelsven P, Attarian S, Blomkwist-Markens PH, Cornblath DR, Goedee HS, Harbo T, Jacobs BC, Kusunoki S, Lehmann HC, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Umapathi T, Topaloglu HA, Willison HJ. van Doorn PA, et al. Eur J Neurol. 2023 Dec;30(12):3646-3674. doi: 10.1111/ene.16073. Epub 2023 Oct 10. Eur J Neurol. 2023. PMID: 37814552
Guillain-Barre syndrome (GBS) is an acute polyradiculoneuropathy. Symptoms may vary greatly in presentation and severity. ...Based on the PICOs, available literature and additional discussions, we provide flow charts to assist making clinical decisions on diagnosis, treatm …
Guillain-Barre syndrome (GBS) is an acute polyradiculoneuropathy. Symptoms may vary greatly in presentation and severity. ...Based on …
Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach.
Stino AM, Naddaf E, Dyck PJ, Dyck PJB. Stino AM, et al. Muscle Nerve. 2021 Feb;63(2):157-169. doi: 10.1002/mus.27046. Epub 2020 Sep 11. Muscle Nerve. 2021. PMID: 32914902 Free article. Review.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, often affecting patients' ability to walk and perform activities of daily living independently. ...
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, often aff …
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.
Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, Attarian S, Blomkwist-Markens PH, Cornblath DR, Eftimov F, Goedee HS, Harbo T, Kuwabara S, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Sommer C, Topaloglu HA. Van den Bergh PYK, et al. J Peripher Nerv Syst. 2021 Sep;26(3):242-268. doi: 10.1111/jns.12455. Epub 2021 Jul 30. J Peripher Nerv Syst. 2021. PMID: 34085743 Free article.
To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (PICO) questions regar …
To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Seventeen disease experts …
POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.
Dispenzieri A. Dispenzieri A. Am J Hematol. 2019 Jul;94(7):812-827. doi: 10.1002/ajh.25495. Epub 2019 May 23. Am J Hematol. 2019. PMID: 31012139 Free article. Review.
Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced eGFR. RISK-ADAPTED THERAPY: For those patients with a dominant sclerotic plasmacytoma, first line therapy is irradiation. ...Thalidomide and bortezomib also have activ …
Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced eGFR. RISK-ADAPTED THERAPY: For th …
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.
Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, Attarian S, Blomkwist-Markens PH, Cornblath DR, Eftimov F, Goedee HS, Harbo T, Kuwabara S, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Sommer C, Topaloglu HA. Van den Bergh PYK, et al. Eur J Neurol. 2021 Nov;28(11):3556-3583. doi: 10.1111/ene.14959. Epub 2021 Jul 30. Eur J Neurol. 2021. PMID: 34327760 Free article.
OBJECTIVE: To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). METHODS: Seventeen disease experts, a patient representative, and two Cochrane methodologists constructed 12 Population/Intervention/Comparison/Outcome (P …
OBJECTIVE: To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). METHODS: Seven …
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.
Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G. Adams D, et al. J Neurol. 2021 Jun;268(6):2109-2122. doi: 10.1007/s00415-019-09688-0. Epub 2020 Jan 6. J Neurol. 2021. PMID: 31907599 Free PMC article. Review.
Symptoms may be mistakenly attributed to other diseases such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), idiopathic axonal polyneuropathy, lumbar spinal stenosis, and, more rarely, diabetic neuropathy and AL amyloidosis. ...Patients should be follo …
Symptoms may be mistakenly attributed to other diseases such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), idi …
POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management.
Dispenzieri A. Dispenzieri A. Am J Hematol. 2021 Jul 1;96(7):872-888. doi: 10.1002/ajh.26240. Epub 2021 May 31. Am J Hematol. 2021. PMID: 34000085 Free article.
Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced eGFR. RISK-ADAPTED THERAPY: For those patients with a dominant plasmacytoma, first line therapy is irradiation. ...Thalidomide and bortezomib also have activity, but t …
Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced eGFR. RISK-ADAPTED THERAPY: For th …
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Bunschoten C, et al. Lancet Neurol. 2019 Aug;18(8):784-794. doi: 10.1016/S1474-4422(19)30144-9. Epub 2019 May 7. Lancet Neurol. 2019. PMID: 31076244 Review.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune-mediated neuropathy. ...
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune-mediated neuropathy …
Diagnosis, treatment and prognosis of Guillain-Barre syndrome (GBS).
van Doorn PA. van Doorn PA. Presse Med. 2013 Jun;42(6 Pt 2):e193-201. doi: 10.1016/j.lpm.2013.02.328. Epub 2013 Apr 28. Presse Med. 2013. PMID: 23628447 Review.
About 5% of patients initially diagnosed with GBS turn out to have chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with acute onset (A-CIDP). It is yet unknown whether GBS patients who remain able to walk ('mildly affected GBS patients'), or patients with …
About 5% of patients initially diagnosed with GBS turn out to have chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) w …
POEMS syndrome: Update on diagnosis, risk-stratification, and management.
Dispenzieri A. Dispenzieri A. Am J Hematol. 2023 Dec;98(12):1934-1950. doi: 10.1002/ajh.27081. Epub 2023 Sep 21. Am J Hematol. 2023. PMID: 37732822
Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced estimated glomerular filtration rate. RISK-ADAPTED THERAPY: For those patients with a dominant plasmacytoma, first-line therapy is irradiation. ...Daratumumab combinat …
Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced estimated glomerular filtration rate. RIS …
159 results